Neurodegenerative Clinical Outcomes | Achieving GCT Success - 2021 World Medical Innovation Forum
May 2–4, 2022

Neurodegenerative Clinical Outcomes | Achieving GCT Success

Neurodegenerative Clinical Outcomes | Achieving GCT Success

Friday, May 21, 2021

10:10 AM – 10:35 AM
Hot Topics

Can stem cell-based platforms become successful treatments for neurodegenerative diseases?

  •  What are the commonalities driving GCT success in neurodegenerative disease and non-neurologic disease, what are the key differences?
  • Overcoming treatment administration challenges
  • GCT impact on degenerative stage of disease
  • How difficult will it be to titrate the size of the cell therapy effect in different neurological disorders and for different patients?
  • Demonstrating clinical value to patients and payers
  • Revised clinical trial models to address issues and concerns specific to GCT
Bob Carter, MD, PhD
  • Chairman, Department of Neurosurgery, MGH
  • William and Elizabeth Sweet Professor of Neurosurgery, HMS
Erwan Bezard, PhD
  • INSERM Research Director, Institute of Neurodegenerative Diseases
Nikola Kojic, MD, PhD
  • CEO and Co-Founder, Oryon Cell Therapies
Geoff MacKay
  • President & CEO, AVROBIO
Viviane Tabar, MD
  • Founding Investigator, BlueRock Therapeutics
  • Chair of Neurosurgery, Memorial Sloan Kettering
  • Q&A

    10:40 AM – 10:55 AM

the Future of Medicine and AI

May 11–13, 2020 | Boston, MA